High frequency imaging for cerebral amyloid angiopathy
High Frequency Imaging in Patients with Cerebral Amyloid Angiopathy
Ludwig-Maximilians - University of Munich · NCT06128824
This study is trying to see if special brain scans can help understand the risks of bleeding and memory problems in people with cerebral amyloid angiopathy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich (other) |
| Locations | 3 sites (Bonn and 2 other locations) |
| Trial ID | NCT06128824 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with cerebral amyloid angiopathy (CAA), a condition characterized by the deposition of amyloid beta in small cerebral vessels, leading to significant neurological issues. It aims to investigate the relationship between cortical superficial siderosis (cSS) and the risk of intracerebral hemorrhages (ICH) and cognitive decline through high-frequency MRI imaging. The study will include patients with probable CAA and will monitor them with serial imaging to better understand the progression of the disease and its associated risks. The findings could provide insights into the mechanisms behind cSS and its implications for patient management.
Who should consider this trial
Good fit: Ideal candidates for this study are elderly patients diagnosed with probable CAA who exhibit signs of cortical superficial siderosis or have survived lobar intracerebral hemorrhages.
Not a fit: Patients with deep location intracerebral hemorrhages or those with contraindications for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding of cerebral amyloid angiopathy and lead to better management strategies for patients at risk of hemorrhagic events and cognitive decline.
How similar studies have performed: While studies on cerebral amyloid angiopathy have been conducted, the specific focus on high-frequency imaging of cSS and its implications is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Probable CAA according to the modified Boston criteria with evidence of 1. cSS or fSAH 2. lobar ICH survivors without cSS or fSAH * Absence of ICH or microbleed in deep locations (basal ganglia, thalamus, brain stem) * Absence of infratentorial siderosis or infratentorial SAH * MR-/CT-/DS-angiography without evidence of cerebral aneurysm, AVM, AV-fistula or other possible etiology for the observed haemorrhagic manifestations * No history of head trauma resulting in loss of consciousness or radiologically visible traumatic brain injury * Written informed consent by patient herself/himself prior to study enrolment Exclusion Criteria: * Unwillingness to participate in high-frequency (monthly) follow-up * Severe medical condition with expected life expectancy \<1 year * Contraindications for MRI (following local guidelines of the respective study center)
Where this trial is running
Bonn and 2 other locations
- DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn — Bonn, Germany (RECRUITING)
- DZNE/Magdeburg - Universitätsklinikum Magdeburg — Magdeburg, Germany (RECRUITING)
- Insitute for Stroke and Dementia Research — Munich, Germany (RECRUITING)
Study contacts
- Principal investigator: Marco Duering, MD — Institute for Stroke and Dementia Research
- Study coordinator: Martin Dichgans, MD
- Email: martin.dichgans@med.uni-muenchen.de
- Phone: +49 89 4400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cerebral Amyloid Angiopathy, cortical superficial siderosis, DWI+ lesion, serial imaging, disease progression, MRI, cerebrovascular events, focal subarachnoid hemorrhage